Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.

Melanie DemersMaria M AlemanElena KistanovaRobert PetersJoe SalasEkta Seth Chhabra

Published in: Journal of thrombosis and haemostasis : JTH (2022)

Equivalent doses of efanesoctocog alfa and rFVIII had similar efficacy in promoting fibrin clot formation and injury-induced platelet accumulation. The hemostatic potential of efanesoctocog alfa was indistinguishable from that of rFVIII.

Keyphrases

replacement therapy
high glucose
diabetic rats
smoking cessation
cell free
endothelial cells
risk assessment